CASE REPORT

Primary undifferentiated pleomorphic cardiac sarcoma with MDM2 amplification presenting as acute left-sided heart failure

Richard Watson,1 Joseph Frye,2 Megan Trieu,3 Michael X Yang1

SUMMARY
Primary cardiac tumours are a rare clinical entity that can present with myriad of non-specific cardiopulmonary symptoms. We describe a case of a 61-year-old previously healthy woman who presented with progressive dyspnoea and lower extremity swelling, suggestive of acute left-sided heart failure. Transthoracic echocardiogram revealed a large, 3.7×3.2 cm intracardiac mass resulting in severe mitral valvular dysfunction. The patient underwent surgical resection of the mass, however, negative margins were not obtained, and the tumour quickly returned. Histological and molecular analysis was consistent with the diagnosis of undifferentiated pleomorphic sarcoma with murine double minute 2 (MDM2) amplification. Given the overall grim prognosis, the patient chose to pursue comfort-based care. She died at home 9 months after the initial diagnosis. Here, we provide an updated review of the literature for the classification of undifferentiated pleomorphic cardiac sarcoma and potential treatment modalities.

BACKGROUND
Primary cardiac tumours are a rare clinical entity. Depending on the exact location, they can present with a variety of cardiopulmonary symptoms, such as left- or right-sided heart failure, embolic phenomena or conduction abnormalities. The majority of cardiac tumours, approximately 75%, are benign myxomas. These typically arise from the left atrium causing mitral valve dysfunction and subsequent left-sided heart failure.1–3 If the tumour is localised and non-invasive, resection is often curative. Cardiac sarcomas, however, are high grade, clinically aggressive neoplasms associated with a poor clinical prognosis. These tumours account for only 10%–20% of all primary cardiac neoplasms and can be further subdivided according to histological features.4

CASE PRESENTATION
A 61-year-old previously healthy woman presented with a 2-week history of progressive shortness of breath, non-productive cough and lower extremity swelling. On initial evaluation, she was found to be...

Figure 1 Initial chest X-ray showed moderate-sized bilateral pleural effusions.
tachycardic (114 beats per min), tachypneic (28 breaths per min) and hypoxaemic on room air (88% SaO2). Physical examination was notable for jugular venous distention, bibasilar crackles, bilateral lower extremity pitting oedema and an apical holosystolic murmur with a mid-diastolic click.

INVESTIGATIONS

Full laboratory analysis, including cardiac biomarkers, was notable only for a mildly elevated B-type natriuretic peptide (179 pg/mL, reference <100 pg/mL) and an elevated D-dimer (1.9 µg/mL fibrinogen equivalent units (FEU), reference <0.70 µg/mL FEU). ECG showed sinus tachycardia without ischaemic changes. Chest X-ray revealed moderate-sized bilateral pleural effusions (figure 1). Given the high D-dimer, a CT angiogram was obtained. This revealed a right middle lobe subsegmental pulmonary embolism and a large, amorphous filling defect in the left atrium, initially thought to be an atrial thrombus. Subsequently, transthoracic echocardiogram (TTE) demonstrated a 3.7×3.2 cm lobulated mass attached to the interatrial wall, causing severe mitral valve dysfunction. A normal left ventricular ejection fraction (67%), severe pulmonary hypertension (pulmonary artery pressure 77 mm Hg) and severe tricuspid regurgitation were also noted (figure 2, videos 1,2).

TREATMENT

The patient was diuresed and underwent bilateral thoracenteses, with prompt symptomatic improvement. She was taken for urgent surgical resection. Intraoperatively, the mass was found to extend from the left atrium, through the interatrial septum, into the right atrium and tricuspid valve. The tumour was debulked, but it was not possible to obtain negative surgical margins due to the extent of invasion into multiple chambers of the heart (figure 3). Histological analysis revealed a high-grade, undifferentiated sarcoma with areas of myxoid differentiation and epithelioid appearing cells. Varying amounts of spindle formation, nuclear atypia, pleomorphism and mitotic figures were also noted (figure 4A–C). Immunohistochemical (IHC) analysis demonstrated desmin positivity, however, other myocyte markers including α-smooth muscle actin, h-caldesmon, myogenin and myoD1 were negative (figure 4D, E). Furthermore, fluorescence in situ hybridisation (FISH) molecular analysis demonstrated amplification of the murine double minute 2 (MDM2) oncogene, supporting the diagnosis of undifferentiated sarcoma (figure 5).

After surgical debulking, the patient’s symptoms were greatly improved. Repeat TTE showed only residual mild mitral regurgitation without mitral stenosis or elevated pulmonary pressures. After extensive discussions with oncology, the patient deferred adjuvant chemotherapy and radiation.

OUTCOME AND FOLLOW-UP

While the patient initially did well, her symptoms eventually returned, and she was readmitted 6 months later. Repeat TTE showed a new mass, measuring 4.3×2.8 cm, attached to the interatrial septum prolapsing through the mitral annulus. She was medically stabilised and discharged with the plan for palliative anthracycline-based outpatient chemotherapy. Over the following 3 months, she was hospitalised three additional times for symptomatic exacerbations. Serial TTEs demonstrated continued enlargement of the left atrial mass, growing...
up to 8×3 cm, with the development of a new right atrial mass (2.6×2.1 cm, figure 6). Given the extent of disease, the patient was not a surgical candidate for further procedures. She was discharged with supportive measures, forgoing optional palliative chemotherapy. She died peacefully at home, approximately 9 months after her initial diagnosis.

**DISCUSSION**

Primary cardiac sarcomas are rare clinical phenomena. The prevalence of primary cardiac tumours has been estimated to be approximately 0.02% (200 tumours per one million people). This is based on a collection of several autopsy series, as the majority of tumours are incidentally found postmortem. Of all primary cardiac tumours, cardiac sarcomas account for only 10%–20% of cases. These malignancies can arise from the mesenchymal cells of the ventricles, atria or pericardium depending on the specific subtype.

The WHO has established a universal classification system for cardiac tumours. The 2004 version identified six subtypes of cardiac sarcomas based on histopathological morphology. High-grade myofibroblastic sarcomas with spindle formation were classified as pleomorphic malignant fibrous histiocytoma (MFH); later to be referred to as undifferentiated pleomorphic sarcoma (UPS). IHC analysis of MFH/UPS is often negative for specific lineage markers, but these tumours can express desmin, vimentin and α-smooth muscle actin to varying degrees. Given the lack of disease-specific markers, the reported frequency of MFH/UPS has varied greatly from less than 10% to over 70% of cases.
all cardiac sarcomas, depending on the histopathological criteria used for classification. In 2014, Neuville et al performed a retrospective analysis of 100 cardiac sarcoma samples in attempt to identify unique molecular markers for the different subtypes. They concluded that the most common type of cardiac sarcoma was intimal sarcoma (42%). Histologically, they described these as high-grade myofibroblastic neoplasms with spindled morphology (similar to the WHO description of MFH/UPS). By molecular analysis, they showed that 100% of these tumours demonstrated amplification of the oncogene MDM2, as determined by FISH. MDM2 protein overexpression was then confirmed using IHC. From this, they classified sarcomas with similar histology, in the absence of MDM2 amplification, as undifferentiated sarcoma (22%).

The term intimal cardiac sarcoma was used in reference to previous studies that showed the majority of pulmonary artery intimal sarcomas displayed MDM2 amplification. Traditionally, the term intimal sarcoma refers specifically to tumours arising from the inner endothelial lining of the great vessels; intima meaning innermost. Clinically, these tumours invade the vascular lumen and present with embolic phenomena, compared with cardiac sarcomas which invade the atria and ventricles, resulting in heart failure. Given this, the updated 2015 WHO guidelines eliminated the term intimal sarcoma in reference to cardiac tumours. It was concluded that due to the lack of specificity for molecular testing (such as MDM2 amplification), the classification of cardiac sarcomas should be based on histological morphology alone. Thus, the title of UPS with or without MDM2 amplification is more suitable for these types of tumours. The prognosis of cardiac sarcomas is overall very poor; median survival is less than 1 year. Surgical resection followed by adjuvant chemotherapy, with or without radiation, is the current standard of care. A recent retrospective review of 124 cases showed that complete resection increased median survival by 7 months (11.2 vs 18.2 months), compared with non-resected patients. However, given the highly invasive nature of these tumours, clear surgical margins are difficult to obtain, and the tumours can easily recur. Due to the rarity of cardiac sarcomas, no randomised clinical trial has been performed to identify an optimal chemotherapeutic regimen. Current treatment modalities are extrapolative, based on protocols for extracardiac sarcomas, including doxorubicin with ifosfamide and gemcitabine with or without docetaxel. The advent of molecular analysis and targeted therapy may offer some promise. On the molecular level, MDM2 regulates the cell cycle by inhibiting the tumour suppressor p53, through ubiquitin-mediated degradation and transcriptional suppression. When upregulated, MDM2 results in aberrant cellular proliferation. In recent years, a number of small molecule inhibitors of MDM2 have been developed which function to stabilise p53 activity. One such MDM2 inhibitor, nutlin-3a, has been shown to be efficacious in haematological malignancies, such as B-cell chronic lymphocytic leukaemia and acute myeloid leukaemia. Another compound, RG7112, has been proven beneficial in dedifferentiated liposarcoma. Finally, due to the central role of p53 in tumourigenesis, there are a number of novel strategies targeting this critical signalling pathway, such as tumour vaccination, microRNAs, oncolytic viruses and immunotherapy.

Acknowledgements We would like to acknowledge the expert pathologists involved in this case, Bonnie Balzer and Daniel Lutheringer and our expert cardiology consult team lead by Bojan Cercek.

Contributors All authors offered substantial contributions to the completion of this paper. RW: conception of work, acquisition of data and writing of manuscript. JF: acquisition of data and writing of manuscript. MT, MXY: conception of work and writing of manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Next of kin obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
1 Burke A, Jeudy J, Vimrani R. Cardiac tumours: an update: cardiac tumours. Heart 2008;94:117–23.
2 Strauss R, Meffiss R. Primary tumor of the heart. Arch Pathol 1945;39:74–8.
3 Perchinsky MJ, Lichtenstein SV, Tyers GF. Primary cardiac tumors: forty years’ experience with 71 patients. Cancer 1997;79:1809–15.
4 Burke AP, Cowan D, Vimrani R. Primary sarcomas of the heart. Cancer 1992;69:387–95.
5 Reynen K. Frequency of primary tumors of the heart. Am J Cardiol 1996;77:107.
6 Burke A, Veintot J, Loire R. Tumours of the lung, pleura, thymus and heart. Tumours of the Heart Lyon: IARC press, 2004:251–88.
7 Orlandi A, Ferlosio A, Roselli M, et al. Cardiac sarcomas: an update. J Thorac Oncol 2010;5:1483–9.
8 Ibrahim A, Luk A, Singhal P, et al. Primary intimal (spindle cell) sarcoma of the heart: a case report and review of the literature. Case Rep Med 2013; 2013:1–5.
9 Neuville A, Collin F, Brunel P, et al. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas. Am J Surg Pathol 2014;38:461–9.
10 Miettinen M. Fibroblastic and myofibroblastic neoplasms with malignant potential. Modern Soft Tissue Pathology. Cambridge, United Kingdom: Cambridge University Press, 2010:348–92.
11 Weiss A, Gill J, Goldberg J, et al. Advances in therapy for pediatric sarcomas. Curr Oncol Rep 2014;16:395.
12 Bode-Leusiewicska B, Zhao J, Speel EI, et al. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery. Virchows Arch 2001;438:57–65.
13 Niini T, Lahiti L, Michelacci F, et al. Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. *Genes Chromosomes Cancer* 2011;50:291–306.

14 Burke AP, Virmani R. Sarcomas of the great vessels. A clinicopathologic study. *Cancer* 1993;71:1761–73.

15 Burke A, Tavora F. The 2015 WHO Classification of tumors of the heart and pericardium. *J Thorac Oncol* 2016;11:441–52.

16 Maleziewski JJ, Tavora F, Burke AP. Do “intimal” sarcomas of the heart exist? *Am J Surg Pathol* 2014;38:1158–9.

17 Truong PT, Jones SO, Martens B, et al. Treatment and outcomes in adult patients with primary cardiac sarcoma: the british columbia cancer agency experience. *Ann Surg Oncol* 2009;16:3358–65.

18 Isambert N, Ray-Coquard I, Italiano A, et al. Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. *Eur J Cancer* 2014;50:128–36.

19 Woll P, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenogastin for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. *Lancet Oncol* 2012;13:1045–54.

20 Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. *J Clin Oncol* 2001;19:3483–9.

21 Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. *J Clin Oncol* 2002;20:2824–31.

22 Merkel O, Taylor N, Prutsch N, et al. When the guardian sleeps: reactivation of the p53 pathway in cancer. *Mutat Res* 2017;773:1–13.

23 Coll-Mulet L, Iglesias-Serret D, Santidrián AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. *Blood* 2006;107:4109–14.

24 Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. *Blood* 2005;106:3150–9.

25 Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. *Lancet Oncol* 2012;13:1133–40.

Copyright 2018 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit http://group.bmj.com/group/rights-licensing/permissions. BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow.